Ridker P, Rifai N, Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. ACC Current Journal Review. 2003;12(2):38.
2. Ridker P, Hennekens C, Buring J, Rifai N. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. New England Journal of Medicine. 2000;342(12):836-843.
3. Ridker P, Danielson E, Fonseca F. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. Journal of Vascular Surgery. 2009;49(2):534.
4. Bohula E, Giugliano R, Leiter L, Verma S, Park J, Sever P et al. Residual Inflammatory and Cholesterol Risk in the FOURIER Trial. Journal of the American College of Cardiology. 2018;71(11):A2.
5. Ridker P, MacFadyen J, Everett B, Libby P, Thuren T, Glynn R et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. The Lancet. 2018;391(10118):319-328.
6. Sureda A, Bibiloni M, Julibert A, Bouzas C, Argelich E, Llompart I et al. Adherence to the Mediterranean Diet and Inflammatory Markers. Nutrients. 2018;10(1):62.
7. Lankinen M, Uusitupa M, Schwab U. Nordic Diet and Inflammation—A Review of Observational and Intervention Studies. Nutrients. 2019;11(6):1369.
8. Ridker P. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk. Journal of the American College of Cardiology. 2018;72(25):3320-3331.
9. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2019) 00-178.
For membership questions and public speaking enquiries, please get in touch